Pacer Advisors Inc. Sells 9,865 Shares of Moderna, Inc. $MRNA

Pacer Advisors Inc. lessened its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 36.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,381 shares of the company’s stock after selling 9,865 shares during the period. Pacer Advisors Inc.’s holdings in Moderna were worth $883,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. MUFG Securities EMEA plc purchased a new stake in Moderna in the 2nd quarter worth approximately $28,000. Flagship Harbor Advisors LLC purchased a new position in shares of Moderna during the fourth quarter valued at approximately $31,000. Canton Hathaway LLC bought a new position in shares of Moderna during the first quarter valued at approximately $31,000. EverSource Wealth Advisors LLC raised its holdings in shares of Moderna by 148.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock valued at $37,000 after acquiring an additional 801 shares in the last quarter. Finally, Assetmark Inc. lifted its stake in Moderna by 35.1% in the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after acquiring an additional 208 shares during the period. Institutional investors own 75.33% of the company’s stock.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: The FDA approved mFLUSIVA, Moderna’s mRNA-based seasonal influenza vaccine, for adults ages 50 and older. It is the first mRNA flu vaccine approved in the United States and Moderna’s fourth FDA-approved product, supporting the company’s effort to diversify beyond COVID-19. The company expects limited retail availability in the coming weeks. US FDA approves first mRNA flu shot from Moderna
• Positive Sentiment: On its second-quarter earnings call, Moderna maintained its 2026 growth target while lowering cost guidance. The combination of preserved revenue expectations and lower spending could improve cash runway and reduce concerns about the company’s post-pandemic revenue decline. Management also highlighted upcoming milestones for flu, oncology and rare-disease programs. Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones
• Positive Sentiment: Moderna began a Phase 1 Canadian trial of an investigational mRNA vaccine for Bundibugyo ebolavirus, a strain without an approved vaccine. Although early-stage, the program reinforces the breadth of Moderna’s infectious-disease platform and its partnerships with CEPI and Canadian public-health authorities. Moderna Starts Phase 1 Canada Trial For Bundibugyo Ebola mRNA Vaccine
• Neutral Sentiment: The flu approval is a meaningful commercial opportunity, but Moderna still needs CDC recommendations, distribution and physician adoption to translate the regulatory win into material revenue. The initial authorization is limited to adults 50 and older, with established flu vaccines already competing for the upcoming season. Moderna Gets FDA Approval for mRNA Flu Vaccine, But CDC Input Still Uncertain
• Negative Sentiment: Investors continue to face substantial execution risk: COVID-related revenue has fallen sharply from pandemic highs, Moderna remains loss-making, and future valuation depends heavily on successful Phase 3 oncology results and broader pipeline commercialization. Some brokerages maintain a “Reduce” view, limiting the immediate impact of the positive headlines.

Moderna Price Performance

NASDAQ:MRNA opened at $59.17 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The firm’s 50-day moving average price is $60.28 and its 200-day moving average price is $53.20. The company has a market capitalization of $23.62 billion, a PE ratio of -7.41 and a beta of 0.91. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $85.60.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. The company had revenue of $145.00 million during the quarter, compared to analysts’ expectations of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. Moderna’s revenue was up 2.1% on a year-over-year basis. During the same period last year, the company posted ($2.13) EPS. On average, equities analysts predict that Moderna, Inc. will post -6.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on MRNA. Morgan Stanley boosted their price objective on shares of Moderna from $33.00 to $39.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 8th. UBS Group reaffirmed an “overweight” rating on shares of Moderna in a research note on Monday, August 3rd. Bank of America increased their price target on shares of Moderna from $34.00 to $38.00 and gave the stock an “underperform” rating in a research note on Tuesday, July 7th. Piper Sandler restated an “overweight” rating on shares of Moderna in a report on Monday, August 3rd. Finally, Jefferies Financial Group reaffirmed a “hold” rating on shares of Moderna in a research report on Thursday, June 18th. Three investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and five have given a Sell rating to the company. According to MarketBeat.com, Moderna has an average rating of “Reduce” and a consensus price target of $42.13.

Insider Transactions at Moderna

In other news, insider Shannon Thyme Klinger sold 3,471 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the sale, the insider directly owned 67,468 shares of the company’s stock, valued at $3,373,400. The trade was a 4.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Noubar Afeyan sold 9,263 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $46.84, for a total value of $433,878.92. Following the completion of the sale, the director owned 3,924 shares in the company, valued at $183,800.16. The trade was a 70.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 119,406 shares of company stock valued at $5,928,762 in the last ninety days. 10.80% of the stock is currently owned by corporate insiders.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.